-
Tytuł:
-
Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT.
-
Autorzy:
-
Cao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Wang M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Shen B; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhao F; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhang R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Chen X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
He Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhai W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Ma Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Wei J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Huang Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Yang D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Pang A; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Feng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jiang E; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Han M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, 70585Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
-
Źródło:
-
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis [Clin Appl Thromb Hemost] 2022 Jan-Dec; Vol. 28, pp. 10760296211068037.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Thousand Oaks, CA : Sage Publications
Original Publication: New York, N.Y. : Raven Press, c1995-
-
MeSH Terms:
-
Recovery of Function*
Blood Platelets/*physiology
Graft Rejection/*drug therapy
Hematopoietic Stem Cell Transplantation/*adverse effects
Recombinant Proteins/*administration & dosage
Thrombocytopenia/*therapy
Thrombopoietin/*administration & dosage
Adolescent ; Adult ; Child ; Female ; Follow-Up Studies ; Graft Rejection/blood ; Humans ; Male ; Middle Aged ; Platelet Count ; Retrospective Studies ; Thrombocytopenia/blood ; Time Factors ; Transplantation, Homologous ; Young Adult
-
References:
-
Front Pharmacol. 2020 Jun 24;11:940. (PMID: 32714186)
Biol Blood Marrow Transplant. 2001;7(3):154-62. (PMID: 11302549)
Biol Blood Marrow Transplant. 2017 Oct;23(10):1678-1684. (PMID: 28642072)
Zhonghua Xue Ye Xue Za Zhi. 2012 Aug;33(8):610-4. (PMID: 23134851)
Int J Clin Pharm. 2015 Feb;37(1):44-52. (PMID: 25432692)
Biol Blood Marrow Transplant. 2019 Sep;25(9):1898-1907. (PMID: 31176790)
Biol Blood Marrow Transplant. 2016 Sep;22(9):1678-1683. (PMID: 27288954)
Blood Adv. 2020 Aug 25;4(16):3829-3839. (PMID: 32790845)
Am J Hematol. 2020 Dec;95(12):1542-1552. (PMID: 32871029)
Platelets. 2020 Oct 2;31(7):939-944. (PMID: 31875757)
Blood Rev. 2018 Nov;32(6):473-479. (PMID: 29699840)
Blood. 2017 Aug 31;130(9):1097-1103. (PMID: 28630121)
Biol Blood Marrow Transplant. 2020 Oct;26(10):1840-1854. (PMID: 32534102)
Annu Rev Med. 1997;48:1-11. (PMID: 9046940)
Bone Marrow Transplant. 2001 Feb;27(3):261-8. (PMID: 11277173)
J Cancer. 2018 Nov 25;9(24):4718-4725. (PMID: 30588257)
Pediatr Transplant. 2017 Sep;21(6):. (PMID: 28653480)
Platelets. 2019;30(8):994-1000. (PMID: 30569802)
Ann Hematol. 2015 Jan;94(1):117-28. (PMID: 25069650)
J Am Acad Dermatol. 2012 Nov;67(5):1025-39. (PMID: 22502948)
Ann Intern Med. 1997 May 1;126(9):673-81. (PMID: 9139552)
J Oncol Pharm Pract. 2017 Jan;23(1):10-17. (PMID: 26471738)
Curr Hematol Rep. 2005 Mar;4(2):137-44. (PMID: 15720963)
Thromb Haemost. 1995 Jul;74(1):521-5. (PMID: 8578518)
Bone Marrow Transplant. 2019 Aug;54(8):1310-1318. (PMID: 30664724)
Biol Blood Marrow Transplant. 2020 Feb;26(2):285-291. (PMID: 31494229)
J Pediatr Hematol Oncol. 2019 Jan;41(1):38-41. (PMID: 30080752)
Chin Med J (Engl). 2015 Aug 5;128(15):2065-71. (PMID: 26228220)
Blood. 2014 Jun 5;123(23):3664-71. (PMID: 24744269)
-
Contributed Indexing:
-
Keywords: allogeneic hematopoietic stem cell transplantation; platelet engraftment; recombinant human thrombopoietin; secondary failure of platelet recovery
-
Substance Nomenclature:
-
0 (Recombinant Proteins)
9014-42-0 (Thrombopoietin)
-
Entry Date(s):
-
Date Created: 20220112 Date Completed: 20220317 Latest Revision: 20220317
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC8761877
-
DOI:
-
10.1177/10760296211068037
-
PMID:
-
35019756
-
Secondary failure of platelet recovery (SFPR) is a life-threatening complication that may affect up to 20% of patients after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, to evaluate the efficacy of recombinant human thrombopoietin (rhTPO), we retrospectively analyzed 29 patients who received continuous rhTPO for the treatment of SFPR. Overall response and complete response were observed in 24 (82.8%) patients and 10 (34.5%) patients, at a median time of 21.5 days (range, 3-41 days) and 39.5 days (range, 7-53 days) after initiation of rhTPO treatment, respectively. Among the responders, the probability of keeping overall response and complete response at 1 year after response was 77.3% and 80.0%, respectively. In multivariate analysis, higher CD34 + cells (≥3 × 10 6 /kg) infused during HSCT (HR: 7.22, 95% CI: 1.53-34.04, P = 0.01) and decreased ferritin after rhTPO treatment (HR: 6.16, 95% CI: 1.18-32.15, P = 0.03) were indicated to associate with complete response to rhTPO. Importantly, rhTPO was well tolerated in all patients without side effects urging withdrawal and clinical intervention. The results of this study suggest that rhTPO may be a safe and effective treatment for SFPR.
